Higher Risks of Gastrointestinal Effects in Diabetic Patients In October 2023, The Journal of the American Medical Association(JAMA), examined adverse events in patients with diabetes associated with GLP-1 RA in a research letter called Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss where it concluded that studies have found increased risks of gastrointestinal adverse events, such as biliary disease, pancreatitis, bowel obstruction, and gastroparesis
After equalizing the treatment disutility due to daily oral treatment administration with that of weekly injection, oral semaglutide 7 mg and 14 mg became dominated by canagliflozin 300 mg and injectable semaglutide 1.0 mg, respectively
This pain may radiate to the back and is often accompanied by nausea and vomiting
B12 injections at a Glance Consultation Required
Is it safe to take B12 every day for energy
While compounded GLP-1 medications may use the same active pharmaceutical ingredients found in branded drugs, the FDA does not review compounded formulations for safety, efficacy, or manufacturing quality in their final form